Disclaimer: CME certification for these activities has expired. All information is pertinent to the timeframe in which it was released.
Lipid Based Cardiovascular Risk Reduction: Practical Strategies for Special Populations
To provide an in-depth analysis of what the guidelines dictate in regard to special populations within coronary heart disease, as well as what impact they will have on practicing cardiologists, internists, primary care physicians, and other health care providers.
This activity is designed for cardiologists, internists, primary care physicians, and other healthcare providers.
After reading this issue, the participant should be able to:
- Identify which therapies should be utilized in the treatment of the adolescent patient with high cholesterol
- Recognize the undertreatment of atherosclerosis in women and identify the possible causes
- Evaluate new clinical data for the treatment of atherosclerosis with combination therapy
- Identify which patient populations do not respond well to systemic therapy
This activity has been planned and produced in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this continuing medical education activity for a maximum of 1 hour in Category 1 credit toward the American Medical Association Physicians' Recognition Award. Each physician should claim only those hours of credit that are actually spent on the educational activity. Credits are available until the expiration date of October 31, 2004.
This continuing education activity was produced under the supervision of Peter O. Kwiterovich, Jr, MD, Professor of Medicine and Pediatrics, Johns Hopkins University School of Medicine, and Director of the Johns Hopkins University Lipid Clinic.
This program is approved for 1 hour of credit (0.1 CEUs) and is co-sponsored by The University of Tennessee College of Pharmacy who is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. ACPE program #064-999-02-222-H01.
This continuing pharmacy education activity was produced under the supervision of Glen E Farr, PharmD, Associate Dean of Continuing Pharmaceutical Education, University of Tennessee College of Pharmacy.
CONTINUING NURSING EDUCATION ACCREDITATION
This educational activity has been approved for 1 contact hour by the Institute for Johns Hopkins Nursing, which is accredited as a provider of continuing education in nursing by the American Nurses' Credentialing Center's Commission on Accreditation. Credit will be awarded until October 31, 2004.
This continuing nursing education activity was produced under the supervision of Kathleen H. Sabatier, MS, RN, Director, The Institute for Johns Hopkins Nursing.
This program is supported by an unrestricted educational grant from Sankyo Pharma.
Publisher's Note and Disclaimer: The opinions expressed in this issue are those of the authors, presenters, and/or panelists and are not attributable to the publisher, editor, advisory board of Advanced Studies in Medicine, or The Johns Hopkins University School of Medicine or its Office of Continuing Medical Education. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this issue are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
Advanced Studies in Medicine (ISSN-1530-3004) is published by Galen Publishing, LLC, an HMG Company. P.O. Box 340, Somerville, NJ 08876. (908) 253-9001. Web site: www.galenpublishing.com. Copyright ©2001 by Galen Publishing, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. Bulk postage paid at Somerville, NJ Post Office and at additional mailing offices. Advanced Studies in Medicine is a registered trademark of The Healthcare Media Group, LLC. Printed on acid-free paper. BPA Membership applied for December 2000.
Peter O. Kwiterovich, Jr, MD
Professor of Medicine and Pediatrics
Johns Hopkins University School of Medicine
Director, Johns Hopkins University Lipid Clinic
Chief, Lipid Research
Johns Hopkins University Hospital
• Dr Kwiterovich reports receiving grants and/or research support from AstraZeneca, Merck, Kos, and Pfizer; and serving as a consultant and receiving honoraria from Merck, Sankyo Pharma, and Kos.
Theodore Feldman, MD
Miami Research Associates
Coral Gables, Florida
• Dr Feldman reports receiving grant and/or research support from Merck, Pfizer, Kos, Bristol-Myers Squibb, AstraZeneca, and GlaxoSmithKline; and serving as a consultant for Merck, Pfizer, Kos, and Sankyo.
Mark Greathouse, MD
Director, Program for the Prevention of Heart Disease
West Penn Allegheny Health System
Allegheny General Hospital
• Dr Greathouse reports serving as a consultant to and receiving honoraria from Bristol-Myers Squibb, Sanofi, Sankyo, and Merck; and receiving grant and/or research support from Bristol-Myers Squibb.
James M. McKenney, PharmD
Virginia Commonwealth University
President and CEO
National Clinical Research
• Dr McKenney reports receiving grant and/or research support from Kos, Sankyo, Bristol-Myers Squibb, Novartis, Pfizer, Merck, and AstraZeneca; serving as a consultant for Pfizer, AstraZeneca, and Sankyo; and receiving honoraria from Pfizer, Merck, AstraZeneca, and Reliant.
Xue-Qiao Zhao, MD
Assistant Professor of Medicine
University of Washington Medical Center
• Dr Zhao reports receiving grant and/or research support from Merck, Pfizer, and AstraZeneca; serving as a consultant for Kos and Sankyo; and receiving honoraria from Merck, Pfizer, Kos, AstraZeneca, and Sankyo.
Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.
The National Cholesterol Education program (NCEP) issued new guidelines for managing hypercholesterolemia that focus on lowering low-density lipoprotein cholesterol (LDL-C) as a primary means of reducing coronary heart disease (CHD) risk.1 As established in previous versions of the Adult Treatment Panel (ATP) guidelines, specific LDL-C target levels are set as treatment goals. Establishing such objective goals not only for LDL-C but also general guidelines for other lipid entities, such as triglycerides and high-density lipoproteins, provides clinicians and patients with objective and practical guides to management. In many cases, dietary modification and exercise will be adequate for achieving the target lipid values. However, more patients now require a more aggressive approach involving drug therapy because the new guidelines set below 100 mg/dL LDL-C as the optimal level. In some high-risk cases (eg, patients hospitalized with coronary events), the guidelines recommend immediate use of drug therapy as opposed to an initial trial of diet therapy.
The NCEP guidelines are based on an extensive review of over 1600 primary references. The evidence ranges from the Lipid Research Clinic Program, which provided the first conclusive evidence that reducing LDL-C with cholestyramine reduced risk of CHD (a 2% risk reduction for every 1% LDL-C reduction),2 through more recent studies showing that 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)3-5 or fibric acid derivatives also showed benefit in primary and secondary prevention.6,7
The new NCEP guidelines are unprecedented in their reliance on the clinical evidence base and are unequivocal in their treatment goals for various lipids. As a result of these treatment goals, the number of patients who qualify for drug treatment nearly tripled, from 13 million to 36 million.8 To assist clinicians in applying the new guidelines to this expanded population, the review article, roundtable discussion, and case study in this issue of Advanced Studies in Medicine will address key issues related to the management of dyslipidemia.
In the roundtable discussion, James M. McKenney, PharmD, an NCEP panelist, pointed out a major shift in the new guidelines: the recognition of certain high-risk patient categories that warrant a more aggressive approach. For example, if patients have type 1 or type 2 diabetes mellitus or have 2 or more risk factors (ie, Framingham-type risk factors) that confer a 10-year risk of more than 20%, they are now considered CHD "risk equivalents." These patients should be managed the same as patients with documented CHD. An LDL-C of 100 mg/dL is the new standard for patients in this newly enlarged high-risk category (Table 1).
According to Dr McKenney, shifting the emphasis from "knowing your number" to "knowing your risk" is a fundamental effect of risk-based treatment. Several recent studies support this concept of aggressively lowering lipids levels in patients in the highest risk categories—including those patients with mild forms of dyslipidemia. The 2001 Diabetes Atherosclerosis Intervention Study, for example, showed that treatment with fenofibrate reduced the progression of atherosclerosis (and presumably CHD risk) in all diabetic patients, including patients with mildly elevated lipid levels.9
The exciting Heart Protection Study offers similar evidence of the broad protective effects of statin therapy in all patients at high risk, again including patients with average-to-low cholesterol levels.10,11 However, this study's results are highly relevant to practicing clinicians because of the size of the undertaking (over 20 000 patients observed for 5 years) and a statistical strength that will allow analysis of specific subsets of previously understudied patient types (eg, women, older people) and outcomes (eg, stroke).
As discussed in this issue's roundtable, the preliminary results from the Heart Protection Study support the concept of aggressively treating all high-risk patients with statins, including patients with LDL-C levels below 130 mg/dL with statins. This study enrolled volunteers aged 40 years to 80 years who were at high risk of CHD (eg, due to prior myocardial infarction, stroke, peripheral vascular disease, or diabetes) but for whom the benefits and safety of cholesterol-lowering therapy were substantially uncertain. Volunteers were given either 40 mg simvastatin or matching placebo tablets and were followed for an average of 5 1/2 years. (The study also evaluated the effects of antioxidant vitamins.) Overall, according to the preliminary data presented at the AHA's 2002 meeting, the statin therapy reduced the risk of heart attacks and stroke by about one third. The benefits were evident not only in women and in people older than 70 years (Table 2), but also in people with "low" cholesterol levels.
Does the new emphasis on risk-driven management mean we should abandon cholesterol measurement altogether? Clearly the answer is no. The cholesterol numbers from the laboratory remain the best guide for identifying risk in patients with no personal or familial history of cardiovascular disease. The numbers provide patients, regardless of their risk factor, and physicians with a tangible guide for treatment and a tool for monitoring progress and encouraging compliance with diet and/or drug treatment. On a population level, the numbers serve as a reminder of what must be done to achieve these newly heightened goals. In the Lipid Treatment Assessment Project, for example, only 38% of the approximately 5000 patients treated in the primary-care setting achieved NCEP-defined cholesterol treatment targets.12 The treatment success rate was only 18% among patients with CHD. One reason for the underaggressive therapy was the clinicians' unwillingness to increase the statin dose.
A main topic of discussion in this issue's roundtable was how to increase success rates in high-risk patients. Increasing the statin dose is one underutilized strategy; combination drug treatment is another. Adding a bile acid resin or niacin to a low-dose statin may provide the extra push toward attaining the LDL-C goal while minimizing the risk of adverse effects sometimes associated with high-dose statin therapy (eg, myositis and liver enzyme elevations). Importantly, the new generation of high-affinity bile acid sequestrants, such as colesevelam, do not provoke the range of gastrointestinal adverse effects associated with the older agents in this class. In a recent clinical trial discussed in this issue's roundtable, colesevelam combined with low-
dose atorvastatin provided a reduction in LDL-C that was essentially equivalent to that provided by 80 mg atorvastatin.13 Additional benefits in terms of high-density lipoprotein increases and triglyceride reduction were also noted.
The new NCEP guidelines and the major clinical trials published in 2001 provide guidance on achieving lipid goals in specific patient types. The discussion and background information provided in this issue of Advanced Studies in Medicine will help to clarify the clinical implications of this new information-especially as it relates older people, women, and patients with diabetes.
1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
4. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcomes in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1997;79:756-762.
5. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97:1446-1452.
6. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
7. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341:410-418.
8. NCEP issues major new cholesterol guidelines [news release]. Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health; May 15, 2001.
9. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet. 2001; 357:905-910.
10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326):7-22.
11. Plutzky J. The heart protection study and other developments in atherosclerosis. American Heart Association Scientific Sessions 2001; Day 5, November 15, 2001. American Heart Association Web site. Available at: http://primarycare.medscape.com/Medscape/CNO/2001/aha/Story. cfm?story_id=2549. Accessed July 9, 2002.
12. Pearson TA, Laurora I, Chue H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). Arch Intern Med. 2000;160:459-467.
13. Hunninghake D, Insull W, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158:407-416
*Professor of Medicine and Pediatrics; Director, Lipid Clinic; Chief, Lipid Research, Johns Hopkins University Hospital, Baltimore, Maryland.
|Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.